A nanobody that inhibits the binding of TNFα to TNFR1 and TNFR2, its product and application
By combining the unique CDRs of DY-T002 and DY-T153 nanobodies, an unconventional single-site and monomeric complex is formed, which solves the problems of non-response and immune response of existing anti-TNFα biologics and achieves efficient inhibition of the binding of TNFα to TNFR1 and TNFR2 and blockade of inflammatory signaling pathways.
Patent Information
- Application Number
- CN202611400253.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-09
- Publication Date
- 2026-11-17
AI Technical Summary
Existing anti-TNFα biologics have shown primary non-response or secondary loss of response in some patients, and long-term use may induce immunogenic reactions. Existing nanobodies have difficulty overcoming the 3:3 symmetrical multi-site pattern to effectively inhibit the binding of TNFα to TNFR1 and TNFR2.
Two VHH nanobodies, DY-T002 and DY-T153, are provided, which form a mono-occupying complex and a monomeric complex in 1:1 and 1:1 ratios, respectively. They bind to TNFα through a unique CDR combination, blocking the recognition of TNFR1 and TNFR2.
DY-T002 and DY-T153 can significantly reduce the binding of TNFα to TNFR1 and TNFR2, reduce the release of IL-6 and IL-1β, provide high-affinity binding and concentration-dependent inhibition of downstream inflammatory factors, and achieve complete receptor blockade and cellular-level neutralization.
Smart Images

Figure CN123106897A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of nanobody technology, and in particular to a nanobody, product, and application that inhibits the binding of TNFα to TNFR1 and TNFR2. Background Technology
[0002] Tumor necrosis factor alpha (TNFα) is an important pro-inflammatory cytokine in the tumor necrosis factor superfamily. In vivo, biologically active soluble TNFα exists primarily in the form of homotrimers, which regulate physiological processes such as inflammatory responses, cell survival, and cell death by binding to tumor necrosis factor receptor 1 (TNFR1) and TNFR2. Persistent abnormal activation of TNFα is closely associated with various inflammatory and autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, hidradenitis suppurativa, and non-infectious uveitis.
[0003] Currently, various anti-TNFα biologics (such as monoclonal antibodies and fusion proteins) are available in clinical practice. They mainly neutralize TNFα activity by covering the receptor-binding region of TNFα or forming steric hindrance. However, these existing therapies still have significant limitations: some patients may experience primary non-response or secondary loss of response, and long-term use may induce immunogenicity, leading to reduced efficacy or increased adverse reactions.
[0004] Nanobodies are single-domain antibodies isolated from heavy chain antibodies of camels, consisting only of the variable region (VHH) of the heavy chain. Compared with traditional antibodies, nanobodies have advantages such as small molecular weight, strong tissue penetration, good stability, easy recombinant expression and engineering, and can recognize occult epitopes that are difficult for traditional antibodies to reach, providing broad prospects for the development of novel TNFα inhibitors.
[0005] In the prior art, various single-domain antibodies against TNFα and their multivalent forms have been disclosed in existing literature. For example, international patents WO2004041862A2 and WO2006122786A2 disclose single-domain antibodies against TNFα; Chinese patents CN114591432B and CN114957467B disclose sequence-defined single-domain antibodies against TNFα, and evaluate their function through antigen binding assays, TNFα-induced cytokine release inhibition assays, receptor binding inhibition assays, or cytotoxicity neutralization assays; international patent WO2016202415A1 discloses antibodies that bind to the TNFα trimer conformational epitope.
[0006] However, some reported anti-TNFα antibody complexes exhibit a 3:3 symmetrical multi-site binding pattern, where a closed TNFα trimer simultaneously binds to three identical antibody molecules. For nanobodies that can efficiently inhibit TNFR1 and TNFR2 recognition without relying on complete occupancy of three equivalent sites, systematic research is still lacking in current technology. Therefore, there is an urgent need to provide nanobodies with novel epitope binding properties that can overcome the existing 3:3 binding pattern and effectively inhibit the TNFα signaling pathway. Summary of the Invention
[0007] The purpose of this invention is to provide a nanobody that inhibits the binding of TNFα to TNFR1 and TNFR2. Addressing the problem that the classic 3:3 symmetrical multi-site model cannot cover different dosages and assembly states of TNFα, this invention provides two VHH nanobodies: DY-T002 and DY-T153. DY-T002 forms a single-site complex with one VHH corresponding to one TNFα trimer in a 1:1 ratio; DY-T153 forms a 1:1 complex with TNFα monomers, and its experimental binding posture is incompatible with the space of the closed TNFα trimer. Both VHHs can inhibit the binding of TNFα to TNFR1 and TNFR2.
[0008] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides a nanobody that inhibits the binding of TNFα to TNFR1 and TNFR2, the nanobody comprising a combination of the following complementarity-determining regions CDR1, CDR2, and CDR3: Combination 1: CDR1 shown in SEQ ID NO:2, CDR2 shown in SEQ ID NO:3, and CDR3 shown in SEQ ID NO:4; or Combination 2: CDR1 shown in SEQ ID NO:7, CDR2 shown in SEQ ID NO:8, and CDR3 shown in SEQ ID NO:9.
[0009] Preferably, when the CDR1, CDR2 and CDR3 of the nanobody are combined to form combination 1, the nanobody is DY-T002, whose amino acid sequence is shown in SEQ ID NO:1 and whose encoding nucleotide sequence is shown in SEQ ID NO:5; When the CDR1, CDR2 and CDR3 of the nanobody are combined to form combination 2, the nanobody is DY-T153, whose amino acid sequence is shown in SEQ ID NO:6 and whose encoding nucleotide sequence is shown in SEQ ID NO:10.
[0010] DY-T002 binds to a surface region formed by adjacent TNFα subunits. Crystal structure, mass spectrometry, and ITC results collectively support the view that a TNFα trimer primarily binds to a single DY-T002 molecule. The DY-T002-bound trimer exhibits a slight geometric asymmetry associated with single occupancy, resulting in severe spatial conflicts when the experimentally positioned rigid body is placed in two other symmetrically related locations; the measured geometric differences are compatible with induced fit or conformational selection.
[0011] DY-T153 forms a 1:1 complex with TNFα monomers. When the TNFα monomers in the experimental complex are superimposed back onto the closed TNFα trimer, DY-T153 exhibits extensive spatial overlap with adjacent subunits. SEC yielded a novel component containing both TNFα and DY-T153 with an apparent size smaller than the native TNFα trimer; these results are consistent with DY-T153's recognition and stabilization of the non-trimeric state of TNFα.
[0012] The present invention also provides an engineered binding molecule based on the above-mentioned nanobody, wherein the engineered binding molecule comprises at least one antigen-binding module, each antigen-binding module being independently an amino acid sequence such as VHH as shown in SEQ ID NO:1 or SEQ ID NO:6; the antigen-binding module is directly connected or connected through a flexible peptide, and optionally connected to an Fc domain or an albumin-binding domain.
[0013] More preferably, the engineered binding molecule includes two divalent molecules of VHH as shown in SEQ ID NO:1, a divalent molecule containing two VHH as shown in SEQ ID NO:6, a dual epitope molecule containing VHH as shown in both SEQ ID NO:1 and SEQ ID NO:6, and a fusion molecule optionally linked to an Fc domain or an albumin-binding domain; each VHH module can be directly linked or linked via a flexible peptide.
[0014] The present invention also provides a nucleic acid molecule that encodes the above-mentioned nanobody or the above-mentioned engineered binding molecule.
[0015] Preferably, the nucleic acid molecule is selected from: (i) SEQ ID NO:5; or (ii) SEQ ID NO:10; or (iii) A nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:6 due to the degeneracy of the genetic code.
[0016] The present invention also provides a recombinant expression vector comprising the above-described nucleic acid molecules.
[0017] The present invention also provides a recombinant host cell containing the above-mentioned recombinant expression vector, or having the above-mentioned nucleic acid molecules integrated into its genome.
[0018] The present invention also provides a pharmaceutical composition, characterized in that the pharmaceutical composition comprises the above-described nanobody, or the above-described engineered binding molecule, and a pharmaceutically acceptable carrier, excipient, or stabilizer.
[0019] Preferably, the pharmaceutical composition may contain DY-T002, DY-T153, or a combination thereof, or engineered binding molecules of two types of VHH modules, and is formulated with a pharmaceutically acceptable carrier, excipient, or stabilizer.
[0020] Both DY-T002 and DY-T153 generate reproducible TNFα-specific binding signals, significantly reducing the binding of TNFα to TNFR1 and TNFR2, and decreasing TNFα-induced IL-6 and IL-1β release from THP-1 cells. This invention establishes an in vitro pharmacological evidence chain through three levels: target binding, receptor blockade, and downstream cellular responses; the two molecules expand the design space for TNFα neutralizing molecules through single-site and non-trimeric recognition pathways, respectively.
[0021] The present invention also provides the use of the above-mentioned nanobody, or the above-mentioned engineered binding molecule, or the above-mentioned nucleic acid molecule, or the above-mentioned recombinant expression vector, or the above-mentioned recombinant host cell, or the above-mentioned pharmaceutical composition in the preparation of a medicament for treating TNFα-mediated inflammatory diseases or autoimmune diseases.
[0022] Preferably, the TNFα-mediated inflammatory diseases or autoimmune diseases include rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, hidradenitis suppurativa, or non-infectious uveitis.
[0023] The present invention also provides a separation complex comprising a DY-T002 trimer mono-occupying complex or a DY-T153 monomeric complex, as well as an in vitro TNFα detection reagent, affinity capture medium and research tool comprising the nanobody or engineered binding molecule, for in vitro detection of TNFα, analysis of TNFα oligomeric state or study of TNFα assembly, open and monomeric state.
[0024] The beneficial effects of this invention compared to the prior art are as follows: (1) This invention provides for the first time two anti-TNFα nanobodies with unconventional binding modes, breaking through the long-standing 3:3 symmetrical multi-site paradigm in this field and providing a novel structural design idea for TNFα targeted intervention. Specifically, DY-T002 (SEQ ID NO:1) forms a single-site complex through a 1:1 ratio of one VHH to one TNFα trimer. The crystal structure (resolution 1.52 Å) clearly shows that one TNFα trimer binds only one DY-T002 molecule. The main peak detected by mass spectrometry is about 61 kDa, and the apparent stoichiometry N measured by ITC is 0.328. The three cross-validations confirm the single-site mode. DY-T002 binds to a surface region formed by two adjacent TNFα subunits. The interface involves residues such as Arg107, Arg108, Arg158, Ser162, Tyr163, Gln164, Thr165, Glu203, and Ser223, with an epitope overlap of approximately 70% with TNFR2 binding residues. When this molecule is rigidly placed in two other unoccupied positions according to a triplet symmetry relationship, the shortest interatomic distances of the heavy atoms are approximately 0.50 Å and 0.26 Å, respectively, which are below the severe spatial conflict criterion of 2.20 Å. This demonstrates that its experimental orientation cannot simultaneously accommodate three molecules at symmetrically related positions, thus spatially explaining the mechanism of single-occupied site formation. DY-T153 (SEQ ID NO:6) forms a 1:1 complex with the TNFα monomer. No classic closed trimer was observed in the crystal structure (resolution 1.89 Å). When the experimental complex was rigidly superimposed onto the closed TNFα trimer, DY-T153 exhibited extensive overlap with adjacent subunits, with a minimum heavy atom distance of approximately 0.29 Å. SEC analysis revealed a new component with an apparent size smaller than the natural trimer, confirming its binding posture's incompatibility with the closed trimer's spatial structure and identifying exposed or non-trimeric states involving internal TNFα epitopes. The epitopes of DY-T153 include residues such as Gln137, Tyr195, Val199, Gln225, Tyr227, and Leu233, with approximately 17% residue overlap at the TNFR2 binding interface, a stark contrast to the epitope selection of DY-T002. The precise CDR combinations (SEQ ID NO:2~4 and SEQ ID NO:7~9) and full-length VHH sequences of the two nanobodies mentioned above are not disclosed in the prior art. Their binding modes, spatial compatibility and structural features together constitute the basis for the structural advancement of this invention.
[0025] (2) This invention fully demonstrates the significant functional advantages derived from the aforementioned structural novelty through an in vitro pharmacological evidence chain, including high-affinity binding, complete blockade of natural receptor recognition, and concentration-dependent inhibition of downstream inflammatory factors. SPR kinetic assays show that the apparent KD of DY-T002 reaches 5.17 × 10⁻⁶. -10The apparent KD of M,DY-T153 is 5.68×10 -9 Both M and TNFR1 possess strong binding capabilities at the nanomolar level. In receptor blockade experiments, the KD of TNFα binding alone to TNFR1 was 3.28 × 10⁻⁶. -10 M, the KD for binding to TNFR2 is 1.29 × 10 -11 M; however, after pre-incubation with DY-T002 or DY-T153, the binding responses of the complexes to TNFR1 and TNFR2 were close to baseline, and no fittable binding was detected, indicating that both nanobodies could completely block the interaction between TNFα and the two natural receptors. In THP-1 cell function validation, stimulation with 10 ng / mL TNFα significantly reduced the release of IL-6 and IL-1β at concentrations of 10 nM and 100 nM, with corrected P values as low as 10 compared to the TNFα-only stimulation group. -8 ~10 -12 The inhibitory effect is concentration-dependent. The experimental data at the target binding, receptor blocking, and cellular neutralization levels are consistent, jointly demonstrating that the nanobody provided by this invention possesses definite TNFα neutralizing activity and can effectively inhibit TNFα-mediated inflammatory signaling pathways. This complete receptor blocking and cellular neutralization achieved through a single-site and non-trimeric recognition pathway is not possessed by existing antibodies relying on 3:3 symmetrical multi-site structures, demonstrating a significant advancement in therapeutic efficacy. Furthermore, this invention provides multivalent or dual-epitope engineered binding molecules containing the aforementioned VHH, further expanding the development space for anti-TNFα drugs and providing a new generation of candidate drugs with structural basis and in vitro functional validation for the treatment of TNFα-mediated inflammatory diseases and autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. Attached Figure Description
[0026] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0027] Figure 1 The diagram summarizes the unconventional TNFα recognition modes of two nanobodies, where A is the experimental monoclonal complex of DY-T002 and the rigid body placement model of symmetric related sites, and B is the experimental monoclonal complex of DY-T153 and the rigid body superposition model of closed trimer; the dashed or diagonal lines represent the calculated placement or predicted spatial overlap. Figure 2The above are the SDS-PAGE results of recombinant expression, protease digestion and reverse Ni-NTA purification of DY-T002 and DY-T153 in Example 1 of the present invention, where A is DY-T002 and B is DY-T153. Figure 3 This is an SPR sensing image of DY-T002 and DY-T153 binding to TNFα in Embodiment 2 of the present invention; Figure 4 The overall structure, binding interface, and hydrogen bond network of the TNFα-DY-T002 single-site complex analyzed in Example 3 of this invention are shown in two observation directions. Figure 5 The mass spectrophotometric molecular weight distribution of TNFα, TNFα-DY-T002 and TNFα-NN223 in Example 4 of this invention; Figure 6 This document presents a comparison of the trimer central angles of free TNFα and DY-T002-bound TNFα in Example 4 of the present invention, and a rigid body placement model of DY-T002 symmetric related sites; wherein A is the trimer central angle of TNFα; B is the trimer central angle of DY-T002-bound TNFα; and C is the rigid body placement model of DY-T002 symmetric related sites. Figure 7 This is a three-dimensional rigid body placement and atomic overlap analysis of DY-T002 at two unoccupied symmetrical related positions in the TNFα trimer in Embodiment 4 of the present invention, where A is the front view and B is the top view; Figure 8 This refers to the representative collision residue pairs and minimum heavy atom distance in the DY-T002 rigid body placement model in Embodiment 4 of the present invention; Figure 9 The overall conformation, binding interface, and hydrogen bond network of the TNFα-DY-T153 complex in Example 5 of this invention; Figure 10 The SEC and SDS-PAGE analyses of the TNFα-d and DY-T153 mixed sample in Example 5 of this invention are shown, where A is the SEC of the TNFα-d and DY-T153 mixed sample and B is the SDS-PAGE analysis of the sample. Figure 11 This document presents the experimentally analyzed TNFα monomer-DY-T153 complex from Example 6 of this invention, and its spatial compatibility analysis after being rigidly placed within a closed TNFα trimer. A is a front view of the TNFα monomer-DY-T153 complex; B is a top view of the TNFα monomer-DY-T153 complex; C is a front view of a rigid DY-T153 component placed within a complete TNFα trimer; and D is a top view of a rigid DY-T153 component placed within a complete TNFα trimer. Figure 12This is the top projection of the DY-T153-TNFα monomer complex in Example 6 of the present invention and its rigid superposition model in the closed trimer; where A is the top projection; B is the rigid superposition model, and the oblique line region is the calculated spatial overlap region; Figure 13 SPR analysis of the binding of TNFα and its DY-T002 complex to TNFR1 and TNFR2 in Example 7 of this invention; Figure 14 SPR analysis of the binding of TNFα and its DY-T153 complex to TNFR1 and TNFR2 in Example 7 of this invention; Figure 15 This refers to the effect of DY-T002 on TNFα-induced release of IL-6 and IL-1β from THP-1 cells in Example 8 of the present invention. Figure 16 This describes the effect of DY-T153 on TNFα-induced release of IL-6 and IL-1β from THP-1 cells in Example 8 of this invention. Detailed Implementation
[0028] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0029] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Every smaller range between any stated value or intermediate value within a stated range, and any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.
[0030] Unless otherwise stated, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.
[0031] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be apparent to those skilled in the art. This specification and embodiments are merely exemplary.
[0032] The terms “comprising,” “including,” “having,” “containing,” etc., used in this invention are all open-ended terms, meaning that they include but are not limited to.
[0033] The term "nanobody" or "VHH" in this invention refers to the variable region of a camel heavy chain antibody or a single-domain antibody designed using this domain framework that can independently bind to antigens.
[0034] The term "specific binding to TNFα" as used in this invention refers to the generation of a repeatable binding signal for TNFα that is distinct from the negative control in SPR, BLI, ELISA, SEC co-elution, mass spectrometry, or equivalent assays.
[0035] The term "unconventional binding dose or assembly state" as used in this invention refers to a 3:3 symmetrical multi-site state in which a closed TNFα trimer simultaneously binds three identical antibody molecules, including the trimer mono-site state of DY-T002 and the TNFα monomeric or non-trimeric binding state of DY-T153; this term does not imply that the two antibodies have the same epitope or the same molecular mechanism.
[0036] The term "sequence identity" as used in this invention is calculated based on the proportion of identical residues after alignment, and can be determined using BLAST, Clustal Omega, or equivalent algorithms recognized in the art. Sequence identity can be used for comparison and screening of candidate sequences, but this invention does not use the percentage of sequence identity in the framework region as a sole substitute for the preparation and functional confirmation of specific sequences.
[0037] The term "functional confirmation" in this invention refers to verifying the specific binding of TNFα and the inhibitory activity against the binding of TNFR1 and TNFR2 for each of the specifically prepared candidate molecules. This verification can be performed using SPR, receptor blocking assays, or cell function assays. Merely having frame sequence identity or completing engineered design does not automatically indicate that the candidate molecule has achieved the aforementioned functional confirmation.
[0038] The CDR boundaries listed in this invention are divided according to the IMGT numbering system, and the CDR amino acid sequences are shown as SEQ ID NO:2~4 and SEQ ID NO:7~9, respectively.
[0039] The human TNFα-d used in this embodiment of the invention is mature, soluble human TNFα Val77-Leu233. Unless otherwise stated, the TNFα residues are numbered according to the human TNFα precursor sequence UniProt P01375.
[0040] The term "primary 1:1 stoichiometry" in this invention refers to the fact that, in the main complex group for crystal structure and corresponding solution biophysical detection, one TNFα trimer corresponds to one DY-T002 molecule; other trace components below the detection limit are not excluded.
[0041] The term "open conformation or non-trimeric state" as used in this invention includes states in which the subunit gap of the closed TNFα trimer increases, partially dissociates, or forms TNFα monomers.
[0042] This invention relates to the following sequence: SEQ ID NO:1 (DY-T002 VHH amino acid sequence): VQLQESGGGLVQPGGSLRLSCAASGSIFSIVGMGWYRRAPGKQRELVAAITSGGRTNYADSVKGRFTISRDNGEDTVYLQMNSLKPEDTAVYYCNVLDSAGMNDYWGQGTQVTVS; SEQ ID NO:2(DY-T002 CDR1): GSIFSIVGMG; SEQ ID NO:3(DY-T002 CDR2): TSGGRTNY; SEQ ID NO:4(DY-T002 CDR3): NVLDSAGMNDY; SEQ ID NO:5 (DY-T002 encoding nucleotide sequence, 5′→3′): GTGCAACTGCAGGAAAGCGGTGGTGGCCTGGTTCAGCCTGGTGGTTCACTGCGTCTGAGCTGCGCAGCTAGTGGCTCAATTTTTAGTATTGTTGGTATGGGTTGGTACCGTCGTGCACCGGGTAAACAGCGCGAACTGGTTGCCGCAATTACCAGTGGCGGTCGCACCAATTATGCAGATAGCGTTAAAGGCCGTTTTACCATTAGTCGTGATAATGGTGAAGACACCGTGTATCTGCAGATGAATAGCCTGAAACCGGAAGATACCGCCGTGTATTATTGTAATGTGCTGGATAGTGCCGGCATGAATGATTATTGGGGCCAGGGCACCCAGGTGACCGTTAGC; SEQ ID NO:6 (DY-T153 VHH amino acid sequence): QVQLQESGGGLVQPGGSLRLSCAASGSIFRINALGWYRQAPGKKRELAAIIASDVSTNYADSVKGRFTISRDNAKNTVYLQMDSLKPEDTAVYYCNAIVQTGVGGPQVYWGQGTQVTVSS; SEQ ID NO:7 (DY-T153 CDR1): GSIFRINALG; SEQ ID NO:8 (DY-T153 CDR2): ASDVSTNY; SEQ ID NO:9 (DY-T153 CDR3): NAIVQTGVGGPQVY; SEQ ID NO:10 (DY-T153 coding nucleotide sequence, 5'→3'): CAAGTTCAATTACAAGAAAGCGGCGGAGGATTAGTACAACCAGGAGGCTCACTTAGATTATCATGTGCAGCATCAGGCTCAATATTTAGAATAAACGCATTAGGATGGTACCGACAAGCACCAGGGAAAAAGCGTGAACTGGCGGCAATTATTGCCAGCGATGTCTCGACTAACTACGCT GATTCCGTCAAAGGCCGTTTTACCATCTCCCGCGATAACGCGAAAAATACCGTTTATCTGCAGATGGATTCACTGAAACCGGAAGATACTGCGGTATATTATTGCAACGCCATTGTTCAAACCGGCGTAGGGGGTCCGCAGGTTTACTGGGGTCAGGGCACCCAGGTGACGGTTAGCTCC.
[0043] Example 1 Example 1 of this invention provides a method for obtaining, expressing, and purifying nanobodies, the specific steps of which are as follows: A VHH library obtained by immunizing alpacas with recombinant human TNFα was used as the starting material for screening. Through multiple rounds of phage display screening, clone sequencing, soluble expression, and TNFα binding verification, the candidate nanobody DY-T002 was obtained. The CDR1, CDR2, and CDR3 of DY-T002 are shown in SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4, respectively; its VHH amino acid sequence is shown in SEQ ID NO:1, and its encoding nucleotide sequence is shown in SEQ ID NO:5.
[0044] Starting with high-throughput sequencing data from the same TNFα-immunized alpaca VHH library, sequence quality control, CDR hierarchical clustering, and candidate sequence screening were performed. The VHH-TNFα complex was predicted using AlphaFold3, and combined with ipSAE interface evaluation and Rosetta structural optimization sequencing, candidate nanobody DY-T153 was obtained. The CDR1, CDR2, and CDR3 of DY-T153 are shown in SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, respectively; its VHH amino acid sequence is shown in SEQ ID NO:6, and its encoding nucleotide sequence is shown in SEQ ID NO:10.
[0045] The nucleic acids encoding DY-T002 and DY-T153 were inserted into the MBPHT (8×His–MBP–SUMO, and transformed into large molecules) fusion expression vectors to obtain the MBPHT–DY-T002 and MBPHT–DY-T153 expression constructs, Enterobacter BL21(DE3). After bacterial culture, isopropyl-β-D-thiogalactoside (IPTG) was added to a final concentration of 0.2 mmol / L, and expression was induced at 19℃ for 16 h. The bacterial cells were collected and lysed, and the soluble supernatant was subjected to Ni-NTA affinity chromatography. The obtained fusion protein was dialyzed to remove the 8×His–MBP–SUMO tag, and then uncleaved fusion protein, free fusion tag, and protease were removed by reverse Ni-NTA chromatography. If necessary, size exclusion chromatography was used for further purification. Using 6 L of culture medium as one preparation batch, approximately 100 mg of the target protein was obtained after tag removal and purification. Based on the culture medium volume, the purification yield was approximately 16.7 mg / L. For SDS-PAGE analysis, 10 μL of sample was loaded per lane. The results are as follows... Figure 2 As shown.
[0046] Figure 2 The results showed that a target band, consistent with the expected molecular weights of DY-T002 and DY-T153, was observed at approximately 14 kDa.
[0047] Example 2 Example 2 of this invention tested the apparent binding kinetic parameters of DY-T002 and DY-T153 from Example 1, as follows: The binding kinetics of DY-T002 and DY-T153 with recombinant human TNFα were determined using a Cytiva Biacore 8K surface plasmon resonance spectrometer. Recombinant human TNFα was immobilized on the surface of a CM5 sensor chip using an amine coupling method. Using PBST as the running buffer, DY-T002 and DY-T153 were prepared into concentration gradients of 62.5, 125, 250, 500, 1000, and 2000 nM, respectively, and flowed sequentially through the chip. Response signals during the 200 s binding phase and 300 s dissociation phase were recorded. The obtained sensing curves were processed using Biacore InsightEvaluation Software and fitted using a 1:1 Langmuir model to calculate the binding rate constant k. a The dissociation rate constant k_d and the apparent equilibrium dissociation constant K_D are shown in the following results. Figure 3 As shown in Table 1.
[0048] Figure 3 As shown in Table 1, both DY-T002 and DY-T153 produced concentration-dependent TNFα binding signals. The fitted signal for DY-T002 was ka = 3.56 × 10⁻⁶. 5 M-1 ·s -1 kd = 1.84 × 10 -4 · s -1 Apparent KD = 5.17 × 10 -10 M; DY-T153's ka = 3.76 × 10 4 M -1 ·s -1 kd = 2.13 × 10 -4 s -1 Apparent KD = 5.68 × 10 -9 M.
[0049] Table 1 Apparent dynamic parameters obtained by fitting with the 1:1 Langmuir model
[0050] Example 3 Example 3 of this invention examined the crystal structure and bonding interface of the DY-T002 complex, and the results are as follows: TNFα and DY-T002 were mixed and incubated, and the complex was purified by SEC. The crystal structure of the TNFα-DY-T002 complex with a resolution of 1.52 Å was obtained through crystallization screening, X-ray diffraction data collection, molecular substitution, and structural refinement. This structure has been submitted to wwPDB, with the structure deposition number D_1300076603.
[0051] The structure shows that TNFα remains in a trimer form, with only one DY-T002 molecule observed binding to each TNFα trimer, i.e., a 1:1 ratio between the TNFα trimer and DY-T002, and a 3:1 ratio between the TNFα subunit and DY-T002. This configuration differs from the 3:3 symmetrical multi-occupied complexes formed by NB11 and NN223 at three equivalent positions.
[0052] DY-T002 primarily utilizes CDR3, with auxiliary contacts provided by CDR2 and the framework region. The TNFα interface includes residues such as Arg107, Arg108, Arg158, Ser162, Tyr163, Gln164, Thr165, Glu203, and Ser223. Results are shown in […]. Figure 4 The overlap between the DY-T002 epitope and the TNFR2 binding residues is approximately 70%.
[0053] Example 4 Example 4 of this invention conducted solution verification and space compatibility analysis of DY-T002 single-site, and the results are as follows: TNFα, TNFα-DY-T002, and TNFα-NN223 were detected by mass spectrometry, and the results are as follows: Figure 5 As shown. Figure 5 The results show that the main peak of TNFα is about 52 kDa; the main peak of TNFα-DY-T002 is about 61 kDa, which is close to the theoretical mass of one TNFα trimer binding one DY-T002; and the main peak of TNFα-NN223 is about 87 kDa, which is close to the theoretical mass of one TNFα trimer binding three NN223.
[0054] The apparent binding stoichiometry (N) of DY-T002, measured by ITC, was 0.328. Based on TNFα subunit concentration, this result is consistent with the finding that approximately three TNFα subunits correspond to one DY-T002. The crystal structure, mass spectrometry, and ITC, along with different detection principles, collectively support the dominant single-site pattern.
[0055] The spatial position of the subunits was represented by the geometric centroid of the Cα atom that was matched by the three TNFα subunits. The trimer center was defined by the average position of the three centroids, and the central angles formed by adjacent centroids were calculated. The three central angles of free TNFα were 119.54°, 119.43°, and 121.03°; those of the DY-T002 bound state were 119.63°, 117.37°, and 123.00°; and those of the NB11 symmetric reconstruction structure were 120.00°, 120.00°, and 120.00°. The DY-T002 bound state exhibited a slight geometric asymmetry related to single occupancy; the measured central angles reflected the geometric differences in the bound state, without distinguishing between induced fit and conformational selection. The results are shown in […]. Figure 6 .
[0056] By rigidly placing the already bound DY-T002 in the experimental structure into two unoccupied positions according to the approximately triplet symmetry relationship of the TNFα trimer, without side-chain rearrangement, local conformational relaxation, or energy optimization, the shortest interatomic distances of the heavy atoms were approximately 0.50 Å and 0.26 Å, respectively, which are below the severe spatial conflict criterion of 2.20 Å. These results are obtained from rigid body calculations and are used to evaluate the spatial compatibility of the experimental orientation at symmetry-related positions. The results are shown in [see figure]. Figures 6 to 8 .
[0057] Example 5 Example 5 of this invention examined the structure of the DY-T153 complex, and the results are as follows: TNFα and DY-T153 were mixed and incubated, followed by SEC analysis. The crystal structure of the TNFα-DY-T153 complex with a resolution of 1.89 Å was obtained through crystallization screening, X-ray diffraction data collection, molecular substitution, and structural refinement. This structure has been submitted to wwPDB under the structure deposition number D_1300076602.
[0058] Figure 9The structure shows that DY-T153 forms a 1:1 complex with a TNFα monomer, and no classic closed TNFα trimer was observed. DY-T153 primarily traverses CDR3, with auxiliary contacts provided by CDR1, CDR2, and the framework region; the TNFα interface includes residues such as Gln137, Tyr195, Val199, Gln225, Tyr227, and Leu233. The residue overlap between this epitope and the TNFR2 binding interface is approximately 17%.
[0059] SEC was performed on both the TNFα single sample and the TNFα-DY-T153 mixed sample. The mixed sample showed a new shoulder peak and additional elution peak, located later than the TNFα trimer but earlier than free DY-T153. SDS-PAGE of the corresponding components detected both TNFα and DY-T153 simultaneously, supporting the existence of a stable complex in solution with an apparent size smaller than the TNFα trimer but larger than free DY-T153. The results are shown in [Figure number missing]. Figure 10 .
[0060] Example 6 Example 6 of this invention tested the spatial incompatibility between the binding attitude of DY-T153 and the closed trimer, and the results are as follows: The TNFα monomer in the experimental complex was superimposed with the A chain of the closed TNFα trimer using Cα atoms. After iterative removal of outlier atoms, the RMSD of the 116 commonly matched Cα atoms was approximately 0.54 Å. After rigidly placing DY-T153 while maintaining the observed relative orientation, DY-T153 showed extensive overlap with adjacent B and C chains, with a minimum heavy atom distance of approximately 0.29 Å. (See results below.) Figure 11 and Figure 12 .
[0061] The closed trimer model did not undergo side-chain rearrangement, local conformational relaxation, or energy optimization. Under the aforementioned rigid superposition conditions, the experimentally observed binding posture of DY-T153 is spatially incompatible with the closed TNFα trimer; combined with the SEC results, this indicates that DY-T153 binding involves the exposure of internal epitopes of TNFα or the formation of a non-trimeric state.
[0062] Example 7 Example 7 of this invention tested the blocking effects of TNFR1 and TNFR2 receptors, and the results are as follows: TNFα was pre-incubated with candidate nanobodies to form complexes, and the binding of TNFα or the complexes to TNFR1 or TNFR2 was detected at concentration gradients of 31.25–2000 nM. Controls were set up for TNFα alone, nanobodies alone, TNFα-NB25, and TNFα-Adalimumab.
[0063] Table 2 shows that the KD of TNFα binding to TNFR1 alone is 3.28 × 10⁻⁶. -10 M, the KD for binding to TNFR2 is 1.29 × 10 -11 M. The responses of the TNFα-DY-T002 and TNFα-DY-T153 complexes to TNFR1 or TNFR2 were close to baseline, and no reliable kinetic fit could be obtained; both were recorded as undetectable binding. DY-T002 and DY-T153 alone also did not produce detectable binding to the aforementioned receptors. Results for DY-T002 are shown below. Figure 13 The results of DY-T153 can be found in [link to DY-T153]. Figure 14 .
[0064] Table 2. KD values of analyte binding to receptor
[0065] Example 8 The THP-1 cell function was verified in this embodiment of the invention, and the results are as follows: THP-1 cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C and 5% CO2. Cells were stimulated with recombinant human TNFα at a final concentration of 10 ng / mL, while DY-T002 or DY-T153 at final concentrations of 1, 10, or 100 nM were added. An unstimulated group, a TNFα-only stimulation group, and a 10 nM Adalimumab positive control group were also included. The same batch of cells was used for this experiment, with three parallel culture wells for each treatment group as technical replicates (n=3). Culture supernatants were collected, and IL-6 and IL-1β concentrations were measured by ELISA. Results are expressed as mean ± standard deviation (mean ± SD, pg / mL). Data from the DY-T002 and DY-T153 groups were analyzed using ordinary one-way ANOVA, with the TNFα-only stimulation group serving as a control, and multiple comparisons were performed using the Dunnett method. P_adj represents the P-value after Dunnett's method correction, and P_adj < 0.05 is considered statistically significant between groups; Figure 15 and Figure 16 middle" " indicates that P_adj < 0.0001.
[0066] In L-6 detection, the IL-6 concentrations in the unstimulated group, the TNFα-only stimulation group, and the Adalimumab positive control group were 21.19±11.69, 561.59±14.53, and 181.02±10.89 pg / mL, respectively. The IL-6 concentrations of DY-T002 at 1, 10, and 100 nM were 539.79±3.76, 367.41±20.36, and 261.56±8.87 pg / mL, respectively; compared with the TNFα-only stimulation group, the corresponding P_adj were 0.1941 and 1.40×10⁻⁶, respectively. -9 and 8.47×10 -12 The IL-6 concentrations of DY-T153 at 1, 10, and 100 nM were 550.72±6.78, 368.48±15.62, and 264.00±3.81 pg / mL, respectively, with corresponding P_adj values of 0.6631, 3.83×10⁻⁶, and 3.83×10⁻⁶, respectively. -10 and 2.33×10 -12 .
[0067] In IL-1β detection, the concentrations of IL-1β in the unstimulated group, the TNFα-only stimulation group, and the Adalimumab positive control group were 0.43±0.20, 233.41±2.82, and 43.30±8.96 pg / mL, respectively. The IL-1β concentrations of DY-T002 at 1, 10, and 100 nM were 232.35±3.00, 160.36±11.79, and 109.68±6.48 pg / mL, respectively; compared with the TNFα-only stimulation group, the corresponding P_adj were 0.9998 and 7.83×10⁻⁶, respectively. -8 and 1.80×10 -10 The IL-1β concentrations of DY-T153 at 1, 10, and 100 nM were 241.76±2.23, 160.23±12.72, and 104.07±5.04 pg / mL, respectively, with corresponding P_adj values of 0.4604, 8.03×10⁻⁶, and 8.03×10⁻⁶, respectively. -10 and 1.12×10 -10 .
[0068] Under the experimental conditions, DY-T002 and DY-T153 showed no significant difference compared to the TNFα-stimulated group at 1 nM, but significantly reduced IL-6 and IL-1β release at 10 and 100 nM. Furthermore, the mean values decreased further with increasing antibody concentration, showing a concentration-related inhibitory trend. (See results below.) Figure 15 and Figure 16 This indicates that DY-T002 and DY-T153 possess TNFα neutralizing activity at the cellular level under the experimental conditions.
[0069] In the above examples, Example 2 demonstrated that both VHHs could bind TNFα with an apparent KD of less than nanomolar; Example 7 demonstrated that the pre-formed TNFα-VHH complex did not show any detectable binding to TNFR1 and TNFR2; Example 8 further demonstrated that both VHHs reduced TNFα-induced IL-6 and IL-1β release at 10 nM and 100 nM. The three levels, using different detection principles and obtaining consistent results, collectively demonstrate that DY-T002 and DY-T153 possess TNFα-neutralizing in vitro pharmacological activities.
[0070] The above embodiments are of the same type as those used in existing anti-TNFα single-domain antibody technologies, such as receptor binding inhibition, cytokine release inhibition, or neutralization pathways in TNFα-sensitive cells. In addition, this invention adds cross-validation of unconventional binding modes using high-resolution structures, mass spectrometry, and ITC.
[0071] Humanization, deimmunogenization, and optimization of solubility or stability can be considered as subsequent candidate design pathways. For framework region candidate replacements, solvent-exposed sites should be prioritized, away from the CDR, Vernier region, and the antigen contact surface shown in the structure of this invention, avoiding the introduction of new undesirable glycosylation, deamidation, isomerization, oxidation, or protease-sensitive sites. Each specific candidate sequence should be actually prepared and confirmed sequentially through purity / monomer status, TNFα binding, TNFR1 / TNFR2 blocking, and cell function assays; this invention does not substitute unmeasured framework identity percentages for functional confirmation.
[0072] In this invention, the VHH coding sequences shown in SEQ ID NO:1 and / or SEQ ID NO:6 can be linked together to construct homologous bivalent or DY-T002-DY-T153 dual epitope candidate molecules. The VHH modules can be directly linked or linked via flexible peptides that do not impede the independent folding of each module, and can optionally be fused with an Fc domain or an albumin-binding domain. Candidate constructs can be obtained by conventional DNA synthesis or recombinant assembly to obtain expression vectors, prepared according to Example 1 or a suitable mammalian cell expression system for fusion proteins, and validated one by one using SEC, SPR, receptor blocking, and cell function assays. Unless otherwise specified, this section describes feasible construction and screening pathways and does not imply that all candidate formats have achieved synergistic effects.
[0073] The nanobodies or functionally confirmed binding molecules can be formulated into pharmaceutical compositions with pharmaceutically acceptable buffers, isotonic modifiers, sugars, surfactants, stabilizers, or lyophilization protectants. The pharmaceutical compositions may contain DY-T002, DY-T153, or both. Examples 2, 7, and 8 demonstrate the in vitro TNFα neutralizing activity of DY-T002 and DY-T153 at the levels of TNFα binding, TNFR1 / TNFR2 receptor binding inhibition, and inhibition of THP-1 cell inflammatory cytokine release, respectively. Therefore, the nanobodies, binding molecules, or pharmaceutical compositions can be used to prepare drugs that inhibit TNFα-mediated signaling pathways, particularly for the treatment of TNFα-mediated inflammatory diseases or autoimmune diseases.
[0074] DY-T002, DY-T153, or their engineered conjugate molecules can be immobilized on microplates, magnetic beads, chips, or sensors via primary amines, thiol groups, enzyme tags, or biotinylation, or linked to enzymes, fluorescent groups, chemiluminescent groups, or magnetic particles to create in vitro TNFα detection reagents, affinity capture media, or research tools.
[0075] In in vitro detection or research methods, the sample to be tested is brought into contact with the detection reagent, affinity capture medium, or research tool, and the binding signal is detected. DY-T002 can be used to detect or capture the outer surface of TNFα trimers and their single-site complexes, while DY-T153 can be used to enrich or analyze TNFα monomers, open or other non-closed trimer states; both, alone or in combination, can be used to study the oligomeric state of TNFα and to screen molecules that affect TNFα assembly or TNFR binding.
[0076] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A nanobody that inhibits the binding of TNFα to TNFR1 and TNFR2, characterized in that, The nanobody comprises a combination of the following complementarity-determining regions CDR1, CDR2, and CDR3: Combination 1: CDR1 shown in SEQ ID NO:2, CDR2 shown in SEQ ID NO:3, and CDR3 shown in SEQ ID NO:4; or Combination 2: CDR1 shown in SEQ ID NO:7, CDR2 shown in SEQ ID NO:8, and CDR3 shown in SEQ ID NO:
9.
2. The nanobody for inhibiting the binding of TNFα to TNFR1 and TNFR2 according to claim 1, characterized in that, When the CDR1, CDR2, and CDR3 of the nanobody are combined to form combination 1, the amino acid sequence of the nanobody is as shown in SEQ ID NO:1; when the CDR1, CDR2, and CDR3 of the nanobody are combined to form combination 2, the amino acid sequence of the nanobody is as shown in SEQ ID NO:
6.
3. An engineered binding molecule based on the nanobody of claim 1 or 2, characterized in that, The engineered binding molecule comprises at least one antigen-binding module, each antigen-binding module being an independent amino acid sequence such as VHH as shown in SEQ ID NO:1 or SEQ ID NO:6; the antigen-binding module is directly connected or connected via a flexible peptide, and optionally connected to an Fc domain or an albumin-binding domain.
4. A nucleic acid molecule, characterized in that, The nucleic acid molecule encodes the nanobody of claim 1 or 2 or the engineered binding molecule of claim 3.
5. The nucleic acid molecule according to claim 4, characterized in that, The nucleic acid molecules are selected from: (i) SEQ ID NO:5; or (ii) SEQ ID NO:10; or (iii) A nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:1 or SEQ ID NO:6 due to the degeneracy of the genetic code.
6. A recombinant expression vector, characterized in that, The recombinant expression vector comprises the nucleic acid molecule as described in claim 4 or 5.
7. A recombinant host cell, characterized in that, The recombinant host cell contains the recombinant expression vector as described in claim 6, or its genome integrates the nucleic acid molecule as described in claim 4 or 5.
8. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises the nanobody of claim 1 or 2, or the engineered binding molecule of claim 3, and a pharmaceutically acceptable carrier, excipient, or stabilizer.
9. Use of a nanobody according to claim 1 or 2, or an engineered binding molecule according to claim 3, or a nucleic acid molecule according to claim 4 or 5, or a recombinant expression vector according to claim 6, or a recombinant host cell according to claim 7, or a pharmaceutical composition according to claim 8, in the preparation of a medicament for treating TNFα-mediated inflammatory diseases or autoimmune diseases.
10. The application according to claim 9, characterized in that, The TNFα-mediated inflammatory or autoimmune diseases include rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, hidradenitis suppurativa, or non-infectious uveitis.
Citation Information
Patent Citations
Single-domain antibodies against TNFα and their applications
CN114591432B
Nanobodies that specifically bind TNF-α and their applications
CN114957467B
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2004041862A2
Improved nanobodies against tumor necrosis factor-alpha
WO2006122786A2
Antibody epitope
WO2016202415A1
